Viridia, a new company, is a wholly-owned subsidiary of ATAI Life Sciences AG, a global biotech platform. The company will generate multiple DMT products “based on alternative routes to intravenous administration.” This is a common method for giving DMT. Ultimately, Viridia will leverage ATAI Life Science’s drug development expertise.
Novel Products to Simplify In-Clinic DMT Administration
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company…
JOIN THE ATAI #INSIGHTNETWORK